Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaMar has initiated a Phase I clinical trial of PM060184 for patients with solid tumours.
Subscribe to our email newsletter
PM060184, which is a marine-derived, synthetically-produced compound, had demonstrated strong in vitro and in vivo antitumour activity and a favourable safety profile in preclinical toxicology studies.
The trials will be conducted in the US, France and Spain.
The primary endpoints of the trial will be to identify the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184.
In addition, the drug’s pharmacokinetic profile will be defined and a preliminary evaluation of its antitumour activity in patients will be performed.